Lanvis

Acute myelogenous & lymphoblastic leukaemia.

,Adult & childn 60-200 mg/m² daily.

Should be taken on an empty stomach.

Hypersensitivity.

Discontinue use in patients w/ evidence of hepatic toxicity. Temporarily discontinue use if abnormally large fall in leucocyte & platelet counts occur. Not recommended for maintenance therapy or similar long-term continuous therapy due to high risk of hepatic toxicity w/ vascular endothelial damage. Bone marrow suppression leading to leucopoenia & thrombocytopenia. Increased susceptibility to infections. Patients w/ inherited deficiency of thiopurine methyltransferase enzyme & NUDT15 gene variant; Lesch-Nyhan syndrome. Monitor FBCs & hepatic function tests wkly during therapy. Asian patients. Limit exposure to sun- & UV light. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended w/ live vaccines until at least 3 mth after completing chemotherapy. Combination w/ other immunosuppresive or chemotherapeutic agents. Hepatic or renal impairment. Avoid use during pregnancy. Not to be used during lactation.

Bone marrow failure; veno-occlusive hepatic disease: hyperbilirubinaemia, hepatomegaly, increased wt, portal HTN: splenomegaly, oesophageal varices, thrombocytopenia, increased hepatic enzyme, blood alkaline phosphatase & γ-glutamyl-transferase, jaundice, portal fibrosis, nodular regenerative hyperplasia, peliosis hepatitis. Stomatitis, GI disorder; veno-occlusive hepatic disease in short-term cyclical therapy; hyperuricaemia, hyperuricosuria, urate nephropathy.

Increased risk of myelosuppression w/ other myelotoxic substances or RT. Not recommended w/ live organism vaccines. Concomitant use w/ aminosalicylate derivatives eg, olsalazine, mesalazine or sulphasalazine.

Cytotoxic Chemotherapy

L01BB03 - tioguanine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer.

B